Trial Profile
Pseudomonas Aeruginosa - Inhalation treatment, biomarkers and quality of life
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs Colistimethate sodium (Primary) ; Piperacillin/tazobactam
- Indications Pseudomonal infections
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 03 Oct 2017 Status changed from recruiting to discontinued.
- 08 Mar 2016 New trial record